Search results
Results from the WOW.Com Content Network
Current cure rates using stem cell therapy in dogs approximates that achieved in humans, 40-50%. When cost is a factor, prednisone used alone can improve the symptoms dramatically, but it does not significantly affect the survival rate. The average survival times of dogs treated with prednisone and untreated dogs are both one to two months. [1]
The survival time may be longer in large dogs, and the cure rate is 20%. If a tumor is completely removed, usually the pet will receive small doses of radiation in hopes of preventing recurrence. The survival rates are: 1 year: 59%, 3 year: 40%, 5 year: 13%. [14]
One study showed that cats with radical (extensive) initial surgery had a median time to recurrence of 325 days versus 79 days for cats with marginal initial excision. [3] The expression of a mutated form of p53 , a tumor suppressor gene , is found commonly in VAS and indicates a poorer prognosis.
Mast cell tumor on lip of a dog. Veterinary oncology is a subspecialty of veterinary medicine that deals with cancer diagnosis and treatment in animals. Cancer is a major cause of death in pet animals. In one study, 45% of the dogs that reached 10 years of age or older died of cancer. [1]
The first left ventricular assist device (LVAD) system was created by Domingo Liotta at Baylor College of Medicine in Houston in 1962. The first LVAD was implanted in 1963 by Liotta and E. Stanley Crawford. The first successful implantation of an LVAD was completed in 1966 by Liotta along with Dr. Michael E. DeBakey.
Illustration of venereal granulomata on a dog's penis. A canine transmissible venereal tumor (CTVT), also known as a transmissible venereal tumor (TVT), canine transmissible venereal sarcoma (CTVS), sticker tumor and infectious sarcoma, is a histiocytic tumor of the external genitalia of the dog and other canines, and is transmitted from animal to animal during mating.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
During the REMATCH trial, several complications were reported for patients who received the LVAD. They reported post-operative pain after LVAD implantation. During an average 400 days of survival, 30 percent of the devices had an internal failure requiring another operation, and almost every patient who had a re-operation did not survive.